Drug Trial Radar · NCT04494503
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
123
Planned (sponsor's estimate)
Start
Aug 31, 2020
Primary completion
Oct 20, 2024
Study completion Dec 2025
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
APG-2575Drug
APG-2575 orally once daily, every 28 days as a cycle.
RituximabDrug
Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
IbrutinibDrug
Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events of APG-2575 single agentTime frame: Up to 6 cycles (each cycle is 28 days).
- Objective Response Rate (ORR) of APG-2575 single agentTime frame: Up to 6 cycles (each cycle is 28 days).
- Dose Limiting Toxicities (DLT) of combination therapyTime frame: 28 days.
- Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)Time frame: 28 days.
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China · Recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Henan Provincial Oncology Hospital
Zhenzhou, Henan, China · Recruiting
Union Hospital medical college Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China · Recruiting
The First affiliated hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First affiliated hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Fudan University Zhongshan Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
The First Bethune Hospital of Jilin University
Hangzhou, Zhejiang, China · Recruiting
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.